DesCripTion
A 2-month-old full-term male infant presented with worsening tachypnoea and a rapidly enlarging, smooth-topped, infiltrative, bronze-yellow nodule with overlying telangiectasias on the mid-sternum ( figure 1A ). CT imaging demonstrated multiple pulmonary nodules, and enhancing extradural masses compressing the L4-L5 vertebral neural foramina. Immunohistochemical staining of biopsies from skin and pulmonary lesions demonstrated a highly proliferative histiocytosis (figure 1B), which was positively immunoreactive for ALK (anaplastic lymphoma kinase) (figure 1C), CD33 and factor XIIIa, weakly positive for CD68, and negative for CD1a, Langerin, CD34, CD20, CD3, CD43, SOX10, S100, C-KIT, lysozyme and myeloperoxidase. These findings were consistent with a diagnosis of ALK+ histiocytosis with pathological features of juvenile xanthogranulomatosis (JXG). Whole body MRI and positron emission tomography (PET)/ CT imaging (figure 2) confirmed that the extensive pulmonary and compressing spinal cord lesions were fluorodeoxyglucose (FDG)-avid, and further revealed an additional, metabolically active right meningeal/parietal parenchymal brain tumour and extensive mediastinal/abdominal lymphadenopathy. Flourescence in situ hybridization (FISH) and DNA mutation sequencing of the histiocytomas revealed a translocated KIF5B-ALK fusion rearrangement. Together, these findings revealed that this was a rare case of systemic non-Langerhans ALK+ JXG with central nervous system (CNS) involvement (~1%-2% of cases), which has been reported to be associated with significant morbidity and mortality. 1 Langerhans cell histiocytosis (LCH) and JXG are rare histiocytic disorders with clinically variable neoplastic behaviours and are characterised by a clonal proliferation of cells of the monocyte-dendritic lineage. The majority (~80%) of JXG cases present with solitary skin lesions, and can be managed with conservative observation or surgical resection, if cosmetically desired. 1 2 Chemotherapy (eg, corticosteroids and vinca alkaloids) or low-dose radiation therapy has also been employed with success. 2 The ALK-KIF5B fusion is a known oncogenic activating mutation and is frequently identified in lung adenocarcinoma and anaplastic lymphomas.
3 ALK-KIF5B fusions are rare in histiocytic disorders and have been reported in only a handful of cases. The presence of aberrant ALK+ genomic lesions may define a clinically distinct class of aggressive non-Langerhans histiocytic disorders. 3 4 The role and long-term efficacy of targeted ALK inhibitor (eg, crizotinib) therapies in the treatment of ALK+ histiocytic disorders currently remain unknown, but potentially beneficial.
Given the known aggressive nature of ALK mutations in other neoplastic disorders and the presence of systemic and CNS disease in this patient, chemotherapy was initiated with the purine analogue cladribine (2-CDA; 2 -chlorodeoxyadenosine). This drug was chosen based on established efficacy in the treatment of adult and paediatric multifocal, systemic LCH and JXG with CNS involvement. 1 2 Follow-up PET imaging after six cycles of 2-CDA therapy demonstrated a near-complete resolution of all FDG-avid lesions. The patient was subsequently started on low-dose daily 6-mercaptupurine and weekly methotrexate maintenance images in… chemotherapy, and currently remains in remission of disease on follow-up radiological imaging. This case represents a rare case of a haematological disorder with potentially broad implications for the understanding and targeted therapy of other ALK-positive malignancies.
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patient's perspective
"Getting the proper diagnosis for our infant son was a long and winding road. It took multiple scans, specialists, and procedures before we had a name for his rare disorder and an understanding of its extent. Being told there were only three other known cases was a shock and of little comfort. There was no clear path forward or expert consensus on what treatment to pursue, and being such a rare disease, it was difficult to find reliable information and support. We were lucky to have physicians who listened to us and were able to understand his subtle symptoms, and pursue appropriate imaging and thorough testing. Because of this, our son received prompt and effective chemotherapy and is growing and thriving today." 
Learning points

